These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 29928990

  • 1. Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.
    Liu X, Xu X, Shang R, Chen Y.
    Nitric Oxide; 2018 Aug 01; 78():113-120. PubMed ID: 29928990
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
    Böger RH, Bode-Böger SM.
    Semin Thromb Hemost; 2000 Aug 01; 26(5):539-45. PubMed ID: 11129410
    [Abstract] [Full Text] [Related]

  • 5. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
    Böger RH.
    J Nutr; 2004 Oct 01; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
    Böger RH.
    Cardiovasc Res; 2003 Oct 01; 59(4):824-33. PubMed ID: 14553822
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.
    Vallance P, Leiper J.
    Arterioscler Thromb Vasc Biol; 2004 Jun 01; 24(6):1023-30. PubMed ID: 15105281
    [Abstract] [Full Text] [Related]

  • 10. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA.
    Bulau P, Zakrzewicz D, Kitowska K, Leiper J, Gunther A, Grimminger F, Eickelberg O.
    Am J Physiol Lung Cell Mol Physiol; 2007 Jan 01; 292(1):L18-24. PubMed ID: 16891395
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases.
    Leiper J, Vallance P.
    Cardiovasc Res; 1999 Aug 15; 43(3):542-8. PubMed ID: 10690326
    [Abstract] [Full Text] [Related]

  • 13. Asymmetric dimethylarginine, endothelial dysfunction and renal disease.
    Aldámiz-Echevarría L, Andrade F.
    Int J Mol Sci; 2012 Aug 15; 13(9):11288-11311. PubMed ID: 23109853
    [Abstract] [Full Text] [Related]

  • 14. Arginine, arginine analogs and nitric oxide production in chronic kidney disease.
    Baylis C.
    Nat Clin Pract Nephrol; 2006 Apr 15; 2(4):209-20. PubMed ID: 16932427
    [Abstract] [Full Text] [Related]

  • 15. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis.
    Weis M, Kledal TN, Lin KY, Panchal SN, Gao SZ, Valantine HA, Mocarski ES, Cooke JP.
    Circulation; 2004 Feb 03; 109(4):500-5. PubMed ID: 14732750
    [Abstract] [Full Text] [Related]

  • 16. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
    Richir MC, Bouwman RH, Teerlink T, Siroen MP, de Vries TP, van Leeuwen PA.
    JPEN J Parenter Enteral Nutr; 2008 Feb 03; 32(6):613-21. PubMed ID: 18974239
    [Abstract] [Full Text] [Related]

  • 17. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
    Betz B, Möller-Ehrlich K, Kress T, Kniepert J, Schwedhelm E, Böger RH, Wanner C, Sauvant C, Schneider R.
    Transl Res; 2013 Aug 03; 162(2):67-76. PubMed ID: 23707198
    [Abstract] [Full Text] [Related]

  • 18. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems.
    Palm F, Onozato ML, Luo Z, Wilcox CS.
    Am J Physiol Heart Circ Physiol; 2007 Dec 03; 293(6):H3227-45. PubMed ID: 17933965
    [Abstract] [Full Text] [Related]

  • 19. Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.
    Fliser D.
    Eur J Clin Invest; 2005 Feb 03; 35(2):71-9. PubMed ID: 15667575
    [Abstract] [Full Text] [Related]

  • 20. The ability of asymmetric dimethylarginine (ADMA) or monomethylarginine (L-NMMA) to block endothelium-dependent, nitric oxide-mediated relaxation in rat aorta is inversely related to the efficacy of the relaxant stimulus.
    Al-Zobaidy MJ, Martin W.
    Eur J Pharmacol; 2014 Oct 15; 741():171-7. PubMed ID: 25149663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.